A recent review assessing the therapeutic potential for cannabis in counteracting inflammation and oxidative stress (56) concluded that while preclinical evidence supports this, the clinical evidence in humans is not convincing
Having a gastroenterologist involved is particularly relevant given that digestive side effects are among the most common complaints from GLP-1 users
Stem cell therapy for pain offers broader regenerative potential, especially for advanced arthritis or joint degeneration
Taste changes occur in a subset of patients and can appear within 510 days
Wegovy and cardiovascular risk reduction In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
Your provider must document BMI, relevant comorbidities (diabetes, hypertension, cardiovascular markers), and why GLP-1 therapy aligns with clinical guidelines
,aspect=ignore)
